Boehringer Mannheim Gmbh

Maxygen, Inc.

Roche Palo Alto LLC

Hoffmann-la Roche Inc.

Mab Discovery Gmbh

Sanofi Biotechnology

Sanofi Biotechnology Sas

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Stephan Fischer

Michael Brandt

Andreas Schaubmar

Ralf Schumacher

Phillip A Patten

Stefan Seeber

Torben Lauesgaard Nissen

Ulrich Kohnert

Sridhar Viswanathan

Ulrich Martin

Anne Vogt

Harald Kropshofer

Anne Stern

Rainer Rudolph

Friederike Hesse

Hans Koll

Joerg Thomas Regula

Kurt Lang

Ralf Mattes

Hendrik Knoetgen

Christian Schantz

Karsten Beckmann

Erhard Kopetzki

Friedrich Metzger

Hans-Joachim Schoenfeld

Linda Veronique Kazandjian

Sabine Imhof-Jung

Roberto Falkenstein

Heinrich Woog

Adelbert Grossmann

Herwig Brunner

Gunther Schumacher

Georg-Burkhard Kresse

Hans-Otto Beutler

Suryanarayana Sankuratri

Hans-Jorg Markl

Ulrich Brinkmann

Manfred Wozny

Barbel Wurst

Christian Hanke

Hans Joachim Schoenfeld

Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.

Monoclonal anti-IL-1RAcP antibodies

Monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody.

HER-2 binding antibodies

The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Humanized anti-IL-1R3 antibodies

The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fey mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.

Agonistic CD40 antibodies

The present invention relates to methods for treating medical conditions and/or disorders characterized by uncontrolled or abnormal expression of members of the IL1R3 signaling pathway such as IL-1&#x3b1;, IL-I&#x3b2;, IL-33, IL-36, IL1RA and/or IL1R3, as well as variants thereof. More specifically, the present invention relates to anti-IL1R3 antibodies for use in the treatment of an IL1R3-mediated inflammatory condition and/or disorder in a subject. Such conditions and disorders include but are not limited to inflammatory diseases, immune disorders, fibrotic disorders, eosinophilic disorders, infection, pain, a central nervous system disorder, an ophthalmologic disorder, Hereditary Systemic Inflammatory Diseases, and Systemic and Local Inflammatory Diseases and cancer associated chronic inflammation.

Anti-IL-1R3 antibodies for use in inflammatory conditions

The present invention relates to monoclonal antibodies that specifically bind to human IL-1 R7, or a fragment or derivative thereof or a polypeptide that contain at least a portion of said antibody that is sufficient to confer specific IL-1 R7 binding to the polypeptide. The invention also relates to the use of said antibodies in the treatment of a IL-18 mediated disease and pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention.

Antibodies specifically binding to human IL-1R7

The present disclosure relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The disclosure further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The disclosure finally encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.

Monoclonal anti-IL-1RAcp antibodies

The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. The invention also relates to the use of an antibody according to the invention in the treatment of a HER-2 mediated disease. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention, and the use of said composition in the treatment of a HER-2 mediated disease.

Monoclonal antibody that specifically binds the interleukin 1 receptor type 1 (IL-1RAcP), or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616. The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.

Herein are reported glycosylated repeat-motif-molecule conjugate of the following formula: (repeat-motif-molecule&#x2212;linker)&#x2212;conjugation partner&#x2212;(linker&#x2212;repeat-motif-molecule), wherein n and o are independently of each other and independently for each value of m and p integer values of 0 or 1, and m and p are independently of each other integer values of 0 or 1 or 2 or 3 or 4 or 5 or 6 or 7, and wherein the repeat-motif-molecule conjugate comprises at least one oligosaccharide attached to a glycosylation site. Also reported are encoding nucleic acids and method for producing these repeat-motif-conjugates in mammalian cells.

Glycosylated repeat-motif-molecule conjugates

Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

Method for the production of insulin-like growth factor-1

The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.

Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the anti-CCR5 antibody and to the pharmaceutical use of the conjugate.

Conjugate of an antibody against CCR5 and an antifusogenic peptide

Growing community of inventors

Polling, Germany

Stephan Fischer